Systems and methods for antibody engineering
AssigneeDna Twopointo Inc.
InventorsClaes Gustafsson, Sridhar Govindarajan, Jeremy Stephen Minshull
Life of this patent
Estimating the term…
Loading patent…
AssigneeDna Twopointo Inc.
InventorsClaes Gustafsson, Sridhar Govindarajan, Jeremy Stephen Minshull
Estimating the term…
Methods, computer systems, and computer program products for antibody engineering. A variant set for an antibody of interest is constructed by identifying, using a plurality of rules, a plurality of positions in the antibody of interest and, for each respective position in the plurality of positions, substitutions for the respective position. The plurality of positions and the substitutions for each respective position in the plurality of position collectively define an antibody sequence space. A variant set comprising a plurality of variants of the antibody is selected. A property of all or a portion of the variants in the variant set is measured. A sequence-activity relationship is modeled between (i) one or more substitutions at one or more positions of the antibody of interest represented by the variant set and (ii) the property measured for all or the portion of the variants in the variant set. The variant set is redefined to comprise variants that include substitutions in the plurality of positions that are selected based on a function of the sequence-activity relationship.
A method for determining a measure of confidence for a descriptor in a first sequence activity relationship for an antibody of interest, the method comprising:
The method of 40 wherein the cells grown in the culture are tumor cells, a cell line derived from tumor cells, a cell line derived from breast cancer cells, a cell line derived from ovarian cancer cells, a cell line derived from lung cancer cells, a cell line derived from bone cancer cells, a cell line derived from fibroblast cancer cells, a cell line derived from hematopoetic cancer cells, a cell line derived from testicular cancer cells, a cell line derived from colon cancer cells, a cell line derived from prostate cancer cells, or a cell line derived from leukemia cells.
The method of 42 wherein the specific cell type is a tumor cell type.
Dependencies are inferred from the claim text.